99.5% Purity Anabolic Steroid Powder for Weight Loss with Factory Price Tirzepatide Peptide

• Function: Reduce Weight
• Certification: GMP, ISO, HACCP, QS, KOSHER, NOP, JAS, OCIA
• Age Group: Adults
• Type: Powder
• Gender: Unisex
• Feature: Low-Fat, Sugar-Free, Low-Salt
• Model NO.: peptide
• Packaging: Bottle
• Storage Note: Moisture Proof
• Logo Printing: Without Logo Printing
• Product Type: Injection
• Health Food Approval No.: Sc11344011400267
• Supply Ability: 100000 Piece/Pieces Per Month
• Production Time: 3-7working Days
• Shipping: DHL/FedEx/by Sea/by Air
• Service: OEM/ODM
• Transport Package: Bottle, Sachet, Bulk, Bag
• Specification: 5mg/10mg
• Trademark: customization
• Origin: Guangzhou
• HS Code: 3004909099
• Production Capacity: 100000 Piece/Pieces Per Month

Product Description

Basic Information

 

Model NO.	Cagrilintide	Status	powder
Purity	99.99%	Powder Raw	Yes
Concealed Transportation	Yes	Freight Timeliness	10-15days
Transport Package	Covert Disguise	Specification	1mg-10mg
Trademark	uther	Origin	China
Production Capacity	10000vials/Week

CagriSema injection is a combination therapy that includes the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and the long-acting amylin analog cagrilintide . The therapy has weight loss benefits, but the effect on glycated hemoglobin (HbA1c) is unclear.


The 83rd American Diabetes Association Scientific Conference 2023 (ADA 2023) will be held in San Diego, USA on June 23, local time. A study was announced during the meeting, which evaluated the effectiveness and safety of CagriSema (semaglutide combined with canaglitide) in patients with type 2 diabetes. Results showed that in patients with type 2 diabetes, treatment with CagriSema improved glycemic control and resulted in significant weight loss compared with semaglutide or canaglitide monotherapy and was well tolerated with no new safety concerns. sexual signals.

This multi-center, double-blind, phase 2 trial included a total of 92 patients with a body mass index (BMI) ≥27 kg/m2 from 17 research centers in the United States from August 2 to October 18, 2021, who received metformin with or without metformin. Adult patients with type 2 diabetes (HbA1c 7.5%~10.0%) treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors were randomly assigned in a 1:1:1 ratio to receive a weekly subcutaneous injection of CagriSema ( n=31), semaglutide (n=31), or canaglitide (n=30) (dose escalation to 2.4 mg over 16 weeks) for 32 weeks. Of these patients, 59 (64%) were male. The average age of patients was 58 years old. The primary endpoint of the study was the change in HbA1c from baseline. Secondary endpoints were body weight, fasting glucose, continuous glucose monitoring (CGM) parameters and safety.

Primary endpoints:

At week 32, the proportions of patients with HbA1c <7.0% and ≤6.5% were 89% and 75%, respectively, in the CagriSema group, 69% and 48%, respectively, in the semaglutide group, and 69% and 48%, respectively, in the canaglitide group. 33% and 17%. Additionally, the mean change in HbA1c from baseline to week 32 was higher in the CagriSema group than in the canaglitide group (estimated treatment difference [ETD] -1.3 percentage points [95% CI -1.7 to -0.8]; P < 0.0001), but There was no difference compared with the semaglutide group (ETD -0.4 percentage points [95% CI -0.8 to 0.0]; P=0.075).

The average changes in HbA1c in the 3 groups are:

CagriSema group: -2.2 percentage points;

Semaglutide group: -1.8 percentage points;

Canaglitide group: -0.9 percentage points.
 

Product Details

Purity	99%+
Actual peptide content	Exceed the standard
Cleanliness	Sterile
Test Report	COA  HPLC
Customized top color	Red Yellow Blue Black Purple White Green
Custom content	2mg 5mg 10mg 15mg 20mg 30me etc.
Payment method	Bank Transfer BTC USDT Paypal
Transportation time	7-15days
Disguise	Can provide
Resend policy	According to different countries